Should humans pursue medical and technological interventions to significantly extend life or even transcend biological limits? \\n→ <https://pmc.ncbi.nlm.nih.gov/articles/PMC5684504/>
\n→ <https://www.nature.com/articles/s43587-024-00702-3>
\n→ <https://www.frontiersin.org/journals/aging/articles/10.3389/fragi.2023.1057204/full>
\n→ <https://time.com/archive/6595274/2045-the-year-man-becomes-immortal/>
\n| Misunderstood Figure | \nClarification or Explanation | \n
|---|---|
| "The first person to live to 150 is already alive." | \n|
| →<http://news.bbc.co.uk/2/hi/science/nature/3761310.stm> | \nThis is a speculative claim, not backed by current biomedical data. | \n
| "Ageing is a disease we can cure." | \n|
| →<https://www.nature.com/articles/d41586-024-03936-8> | \nAgeing is a natural biological process, not a single curable condition. | \n
| Misconception | \nCorrection | \n
|---|---|
| "Living longer means suffering longer." | \n|
| →<https://www.who.int/news-room/fact-sheets/detail/ageing-and-health> | \nLongevity research often aims to extend healthy life years, not just life span. | \n
| "Life extension is only for the rich." | \n|
| → <https://theconversation.com/the-rich-are-pouring-millions-into-life-extension-research-but-does-it-have-any-ethical-value-201774> | \nWhile inequalities exist, many innovations may become mainstream like past medical advances. | \n
| Misinformation | \nCorrection or Clarification | \n
|---|---|
| "Cryonics can bring you back to life." | \n|
| → <https://www.scientificamerican.com/article/nano-nonsense-and-cryonic/> | \nCryonics is not proven to revive anyone; it remains speculative. | \n
| "Brain uploading is around the corner." | \n|
| → <https://www.technologyreview.com/2018/03/13/144721/a-startup-is-pitching-a-mind-uploading-service-that-is-100-percent-fatal/> | \nThe required neuroscience is far from being achieved. | \n
| Impact | \nPositively Affected (Individual) | \nPositively Affected (Organisational / Industrial) | \nPositively Affected (Societal) | \nNegatively Affected (Individual) | \nNegatively Affected (Organisational / Industrial) | \nNegatively Affected (Societal) | \n
|---|---|---|---|---|---|---|
| Increased life expectancy | \nElderly individuals, future generations | \nBiotech companies, insurance | \nAgeing societies benefit from experience and productivity | \nPeople with chronic illness, unequal access | \nPublic health budgets may strain | \nInequality, ageing-related tensions | \n
| Biomedical enhancement | \nPeople with disabilities or chronic conditions | \nMedical innovation sectors | \nSocial innovation | \nIndividuals excluded due to cost or beliefs | \nTraditional medical systems disrupted | \nEthical and regulatory dilemmas | \n
| Potential Solution | \nPositively Affected (Individual) | \nPositively Affected (Organisational / Industrial) | \nPositively Affected (Societal) | \nNegatively Affected (Individual) | \nNegatively Affected (Organisational / Industrial) | \nNegatively Affected (Societal) | \n
|---|---|---|---|---|---|---|
| Regulated access to longevity medicine | \nWider affordability | \nPublic healthcare providers | \nEquity-focused development | \nWealthy consumers may lose exclusivity | \nPrivate clinics lose clientele | \nRegulatory burden | \n
| Ethical frameworks for enhancement | \nPersonal autonomy supported | \nPharma companies with clear rules | \nHarmonisation of standards | \nPeople opposed on moral/religious grounds | \nSectors relying on grey areas | \nPolarisation or cultural resistance | \n